Hexabody-CD38, a Novel CD38 Antibody with a Hexamerization Enhancing Mutation, Demonstrates Enhanced Complement-Dependent Cytotoxicity and Shows Potent Anti-Tumor Activity in Preclinical Models of Hematological Malignancies

Bart E. C. G. De Goeij; Maarten L. Janmaat; Grietje Andringa; Laurens Kil; Berris Van Kessel; Kristine A. Frerichs; Andreas Lingnau; Andreas Freidig; Tuna Mutis; A. Kate Sasser; Esther C. W. Breij; Niels W. C. J. Van de Donk; Tahamtan Ahmadi; David Satijn

doi:https://doi.org/10.1182/blood-2019-125788

Hexabody-CD38, a Novel CD38 Antibody with a Hexamerization Enhancing Mutation, Demonstrates Enhanced Complement-Dependent Cytotoxicity and Shows Potent Anti-Tumor Activity in Preclinical Models of Hematological Malignancies

Bart E. C. G. De Goeij, Maarten L. Janmaat, Grietje Andringa, Laurens Kil, Berris Van Kessel, Kristine A. Frerichs, Andreas Lingnau, Andreas Freidig, Tuna Mutis, A. Kate Sasser, Esther C. W. Breij, Niels W. C. J. Van de Donk, Tahamtan Ahmadi, David Satijn

Research output: Contribution to journal › Meeting Abstract › Academic

Original language	English
Journal	Blood
Volume	134
DOIs	https://doi.org/10.1182/blood-2019-125788
Publication status	Published - 13 Nov 2019

Access to Document

https://doi.org/10.1182/blood-2019-125788

Cite this

De Goeij, B. E. C. G., Janmaat, M. L., Andringa, G., Kil, L., Van Kessel, B., Frerichs, K. A., Lingnau, A., Freidig, A., Mutis, T., Sasser, A. K., Breij, E. C. W., Van de Donk, N. W. C. J., Ahmadi, T., & Satijn, D. (2019). Hexabody-CD38, a Novel CD38 Antibody with a Hexamerization Enhancing Mutation, Demonstrates Enhanced Complement-Dependent Cytotoxicity and Shows Potent Anti-Tumor Activity in Preclinical Models of Hematological Malignancies. Blood, 134. https://doi.org/10.1182/blood-2019-125788

@article{6d59cfdd176f4a2497208d9fb664db55,

title = "Hexabody-CD38, a Novel CD38 Antibody with a Hexamerization Enhancing Mutation, Demonstrates Enhanced Complement-Dependent Cytotoxicity and Shows Potent Anti-Tumor Activity in Preclinical Models of Hematological Malignancies",

author = "{De Goeij}, {Bart E. C. G.} and Janmaat, {Maarten L.} and Grietje Andringa and Laurens Kil and {Van Kessel}, Berris and Frerichs, {Kristine A.} and Andreas Lingnau and Andreas Freidig and Tuna Mutis and Sasser, {A. Kate} and Breij, {Esther C. W.} and {Van de Donk}, {Niels W. C. J.} and Tahamtan Ahmadi and David Satijn",

year = "2019",

month = nov,

day = "13",

doi = "https://doi.org/10.1182/blood-2019-125788",

language = "English",

volume = "134",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

}

De Goeij, BECG, Janmaat, ML, Andringa, G, Kil, L, Van Kessel, B, Frerichs, KA, Lingnau, A, Freidig, A, Mutis, T, Sasser, AK, Breij, ECW, Van de Donk, NWCJ, Ahmadi, T & Satijn, D 2019, 'Hexabody-CD38, a Novel CD38 Antibody with a Hexamerization Enhancing Mutation, Demonstrates Enhanced Complement-Dependent Cytotoxicity and Shows Potent Anti-Tumor Activity in Preclinical Models of Hematological Malignancies', Blood, vol. 134. https://doi.org/10.1182/blood-2019-125788

Hexabody-CD38, a Novel CD38 Antibody with a Hexamerization Enhancing Mutation, Demonstrates Enhanced Complement-Dependent Cytotoxicity and Shows Potent Anti-Tumor Activity in Preclinical Models of Hematological Malignancies. / De Goeij, Bart E. C. G.; Janmaat, Maarten L.; Andringa, Grietje et al.
In: Blood, Vol. 134, 13.11.2019.

Research output: Contribution to journal › Meeting Abstract › Academic

TY - JOUR

T1 - Hexabody-CD38, a Novel CD38 Antibody with a Hexamerization Enhancing Mutation, Demonstrates Enhanced Complement-Dependent Cytotoxicity and Shows Potent Anti-Tumor Activity in Preclinical Models of Hematological Malignancies

AU - De Goeij, Bart E. C. G.

AU - Janmaat, Maarten L.

AU - Andringa, Grietje

AU - Kil, Laurens

AU - Van Kessel, Berris

AU - Frerichs, Kristine A.

AU - Lingnau, Andreas

AU - Freidig, Andreas

AU - Mutis, Tuna

AU - Sasser, A. Kate

AU - Breij, Esther C. W.

AU - Van de Donk, Niels W. C. J.

AU - Ahmadi, Tahamtan

AU - Satijn, David

PY - 2019/11/13

Y1 - 2019/11/13

U2 - https://doi.org/10.1182/blood-2019-125788

DO - https://doi.org/10.1182/blood-2019-125788

M3 - Meeting Abstract

SN - 0006-4971

VL - 134

JO - Blood

JF - Blood

ER -

De Goeij BECG, Janmaat ML, Andringa G, Kil L, Van Kessel B, Frerichs KA et al. Hexabody-CD38, a Novel CD38 Antibody with a Hexamerization Enhancing Mutation, Demonstrates Enhanced Complement-Dependent Cytotoxicity and Shows Potent Anti-Tumor Activity in Preclinical Models of Hematological Malignancies. Blood. 2019 Nov 13;134. doi: https://doi.org/10.1182/blood-2019-125788